Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells.
The incorporation of 5-iodo-2'-deoxyuridine (IdUrd), a thymidine analog radiosensitizer, can be increased by the use of modulators such as 5-fluorouracil (FUra). FUra is a particularly attractive potential modulator to use against colorectal cancer, as it is the most active single agent in the treatment of this disease. To begin to define the conditions for the optimal combination of IdUrd and FUra in the treatment of patients with colorectal cancer, a study was conducted of the effect of FUra on IdUrd-mediated radiosensitization in cultured HT29 human colon cancer cells. It was found that when cells were exposed to concentrations of IdUrd typical of those obtained through intravenous exposure (1-3 microM), FUra (1 microM) increased radiosensitization beyond that which would be predicted for the same extent of incorporation produced by incubation with IdUrd alone. This increase appeared to result from a combination of at least two effects: FUra-mediated cell cycle redistribution and increased IdUrd incorporation. When a higher concentration of IdUrd (10 microM) was used with FUra (1 microM), cell cycle distribution returned to nearly normal, and radiosensitization was equal to that predicted by the extent of incorporation of IdUrd. These data demonstrate that the combination of FUra and IdUrd can produce radiosensitization both through increased IdUrd incorporation and cell cycle redistribution. Furthermore, they suggest that, in the presence of a modulator, it may not be necessary to achieve high levels of IdUrd incorporation to produce significant tumor radiosensitization.
Lawrence
T S
TS
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109-0582.
Davis
M A
MA
Maybaum
J
J
Stetson
P L
PL
Ensminger
W D
WD
D002453:Cell Cycle / Q000187:drug effects; D003110:Colonic Neoplasms; D004273:DNA, Neoplasm / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D011836:Radiation Tolerance / Q000187:drug effects*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D011838:Radiation-Sensitizing Agents; D007065:Idoxuridine; D005472:Fluorouracil